InvestSMART

Dimerix Limited (ASX:DXB)

ALERT: Price-sensitive ASX Announcement for DXB
Current share price for DXB : $0.290 0.05 (20.83%)+
Announcement
Release
17 Jul 2026 9:01AM
Price at Release
$0.240
Full Release
download
Summary
Dimerix Limited, a clinical-stage biopharmaceutical company focused on kidney disease treatments, has secured a non-dilutive AU$10 million loan facility from SKIPTAN Pty Ltd to fund the commercial manufacturing of DMX-200 and the initiation of DMX-652 Phase 2 clinical trials. This funding is intended to extend the company's cash runway through the completion of the ACTION3 Phase 3 trial and is part of a broader strategy that includes negotiations for up to AU$40 million in additional funding. The loan comes with a 10% per annum interest rate, compounding annually, and provides financial support for expanding access programs and pipeline development.
Key Points
  • Dimerix Limited secures non-dilutive funding with a AU$10 million loan facility.
  • The funding supports commercial manufacturing of DMX-200 and initiation of DMX-652 Phase 2 trial.
  • Dimerix is funded for the completion of the ACTION3 Phase 3 trial for DMX-200.
  • The company plans to extend cash runway through negotiations for an additional AU$40 million in funding.
  • The loan is provided by SKIPTAN Pty Ltd, an associate of a substantial shareholder.
  • Interest on the loan is 10% per annum, compounding annually.
  • The funding is aimed at expanding access programs and supporting pipeline expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.